NCT04747808

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: MediPrint Ophthalmics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.

Conditions

• Primary Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	LL-BMT1	Drug-printed contact lens in both eyes

Timeline

• Start date: 2021-01-08
• Primary completion: 2021-02-16
• Completion: 2021-02-16
• First posted: 2021-02-10
• Last updated: 2022-06-08
• Results posted: 2022-05-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study